多西他赛为主的联合方案治疗晚期乳腺癌临床研究

A clinical study on combination chemotherapy based on docetaxel in the treatment of advanced breast cancer

目的观察多西他赛为主的联合化疗方案治疗晚期乳腺癌的疗效及毒副反应。方法共有46例晚期乳腺癌病人接受治疗。初次化疗者及既往未使用过葸环类者24例，接受多西他赛加吡柔吡星方案化疗，吡柔吡星40mg／m^2，静脉冲入，d1，多西他赛75mg／m^2，静脉滴注1h，d2；既往使用过葸环类治疗失败者22例，接受多西他赛加顺铂方案化疗，多西他赛75mg／m^2，静脉滴注1h，d1，顺铂25-30mg／m^2，静脉滴注，d2-d5。至少化疗2个周期以后评价疗效，按WHO标准进行评价。结果46例CR3例，PR21例，SD13例，PD9例，有效率52．2％（24／46），毒性反应主要为骨髓抑制和脱发。结论多西他赛为主化疗方案治疗晚期乳腺癌疗效确切，毒性反应能耐受。

Objective To observe the efficacy and toxicity of docetaxel-based combination chemotherapy in the treatment of advanced breast cancer. Methods Of forty-six patients with advanced breast cancer, twenty-four patients treated for the first time and haven＇t be given adriamycin-based chemotherapy received the regimen of docetaxel plus pirarubicin, pirarubicin 40mg/m^2, intravenous injection, dl, docetaxel 75mg/m^2, 1-hour intravenous infusion, d2; Twenty-two patients previously failed to adriamycin-based chemotherapy received the regimen of docetaxel plus cisplatin, docetaxel 75mg/m^2, 1-hour intravenous infusion, dl, cisplatin 25-30mg/m^2, intravenous infusion, d1-5. The regimen was repeated every 21-28 days and the clinical response was assessed after two cycles. Results Of forty-six patients after treatment by docetaxel-based combined chemotherapy, 3 were CR, 21 were PR, 13 were SD, and 9 were PD. The overall response rate was 52.2%（24/46）. The major toxicities included myelosuppression and alopecia. Conclusions Docetaxel-based combined chemotherapy is effective in the treatment of patients with advanced breast cancer and toxicities are tolerable.